Three Stocks Nobody's Talking About That Could Actually Make You Money Right Now
A psychedelic biotech, a rare earth pure-play, and a private credit machine walk into a bar — and they're all under $10B market cap
Ticker Ratings
Everyone's busy doom-scrolling Iran ceasefire headlines and debating whether John Ternus can out-Steve-Jobs Tim Cook. Meanwhile, three genuinely interesting small-caps are doing things that actually matter for your portfolio — and Reddit hasn't fully caught on yet.
$CMPS (Compass Pathways) just had its best single day since 2020, ripping 42% after Trump signed an executive order to fast-track psychedelic drug research. The FDA is cutting review times from 6-10 months to 1-2 months via breakthrough designation and dropping $50 million into psychedelic research — that's a regulatory tailwind that doesn't come along often. With 30-40% PTSD remission rates where SSRIs go to die, the clinical case is compelling and the policy door just swung wide open.
$USARE (USA Rare Earth) surged ~13% on a $2.8 billion acquisition of Brazil's Sara Verde Group and a fresh Wedbush outperform initiation. As the US sprints to build rare earth supply chains outside China, this company is quietly becoming infrastructure — the kind Wall Street eventually has to own whether it wants to or not.
$OBDC (Blue Owl Capital Corporation) doesn't get the headlines but it's eating traditional banks' lunch. Private credit and BDCs are structurally taking share, and Blue Owl runs at under 1x leverage with 75% of fees structured for durability — making the Jamie Dimon 'GFC 2.0' scaremongering look like exactly what it is: a banker crying into his bonus pool.
The biggest alpha is always hiding where people aren't looking. And right now, nobody's looking here.